论文部分内容阅读
抗叶酸药物氨甲喋呤(MTX),自50年代问世以来,因其抗癌谱广故已成为临床上常用的一种抗代谢抗癌剂。近些年来通过用药方法上的改革,使其毒性更为减低而疗效有了明显地提高。1968年后发展的“大剂量氨甲喋呤加CF解救”的方法,已被视为肿瘤化学治疗的重大进展之一,Advani等1981年报导中剂量氮甲喋呤(MD-MTX)静脉输注不加叶酸制剂解救的方法治疗38例进展期头颈部癌,有效率高达80％,
Antifolate drug methotrexate (MTX), since the advent of the 50’s, because of its wide spectrum of anti-cancer has become clinically used as an anti-metabolic anti-cancer agent. In recent years, through the reform of drug treatment methods to make it more reduced toxicity and efficacy has been significantly improved. The development of “high-dose methotrexate plus CF rescue” after 1968 has been considered as one of the major advances in chemotherapy for cancer. Advani et al reported in 1981 that mid-dose methotrexate (MD-MTX) Folic acid preparation rescue method for the treatment of 38 cases of advanced head and neck cancer, the effective rate of up to 80%